Schechter Adam H, President & CEO, has demonstrated a consistent pattern of selling activity across two companies—LabCorp (LH) and DaVita (DVA)—with no recorded purchases in the available SEC filings. Over 43 reported transactions, Schechter has exclusively sold shares, totaling approximately $29.8 million in value. The majority of this activity has been concentrated in LabCorp, with notable sales including a $7 million transaction on March 26, 2026, and multiple seven-figure disposals throughout 2025 and early 2026, such as a $2.44 million sale on March 3, 2026, and a $1.51 million transaction on May 12, 2025. Smaller but still significant sales, including a $370,461 trade on February 9, 2026, and a $300,541 disposition on February 11, 2025, further underscore the selling trend.
While Schechter’s filings for DaVita (DVA) show no monetary transactions—only awards or acquisitions with zero reported value—the focus remains overwhelmingly on LabCorp. The absence of any buy transactions suggests a one-directional approach, with Schechter systematically reducing his holdings in LH over time. The most recent activity, including the multimillion-dollar March 2026 sale, reinforces this pattern. The data does not indicate whether these sales are part of a prearranged trading plan, but the consistency and scale of disposals highlight a clear divestment strategy in LabCorp shares.
AI-assisted summary